Curis (FRA:CUS0) YoY EBITDA Growth : 11.76% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Curis YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Curis's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 11.76%.

Curis's EBITDA per Share for the three months ended in Mar. 2024 was €-1.97.

Curis YoY EBITDA Growth Historical Data

The historical data trend for Curis's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis YoY EBITDA Growth Chart

Curis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

2.47

43.48

5.32

-32.40

25.12

Curis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															24.87	29.88	25.40	17.19	11.76

Curis YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Curis's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-7.82	-	-10.444)	/	\| -10.444 \|
=	25.12 %

Curis's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-1.973	-	-2.236)	/	\| -2.236 \|
=	11.76 %

Curis YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Curis's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Curis (FRA:CUS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CRIS:USA

Address

128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421

Website

https://www.curis.com

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis (FRA:CUS0) Headlines

No Headlines